AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05646992
Drug: Imuran
RxNorm normalized name: Imuran
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Used as daily immunosuppresion. 100 mg for total body weight less than 75 kg and 150 mg for total body weight greater than or equal to 75 mgs
Trial: NCT05106205
Drug: DA-5213 10mg
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT04763226
Drug: BMS-986308
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04763226
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06199895
Drug: Paclitaxel Polymeric Micelles for Injection
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for ≥ 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.
Trial: NCT04850664
Drug: CBOT + TAU
RxNorm normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The CBOT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time. It is paired with OFC-dependent cognitive tasks.
Trial: NCT04850664
Drug: Sham + TAU
RxNorm normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham CBOT device uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive tasks.
Trial: NCT05304455
Drug: Apixaban 2.5 MG
RxNorm normalized name: apixaban 2.5 MG
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
Trial: NCT05304455
Drug: Dipyridamole 25Mg Tab
RxNorm normalized name: DIPYRIDAMOLE 25MG TAB
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
Trial: NCT05145543
Drug: Levobupivacaine Hydrochloride
RxNorm normalized name: Levobupivacaine Hydrochloride
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25 % levobupivacaine (5 ml) will be applied.
Trial: NCT05145543
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone plus levobupivacaine (5 ml) will be applied.
Trial: NCT05392647
Drug: Hetrombopag
RxNorm normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All eligible patients were given hetrombopag orally at an initial dose of 5 mg once daily after overnight fasting (\>8 hours of fasting) and at least 2 hours before a meal . The dose of hetrombopag could be modified on the basis of the platelet count of patients after 2 weeks of administration.
Trial: NCT00022945
Drug: Iodine-131 Anti-B1 Antibody
RxNorm normalized name: Iodine-131 anti-b1 antibody
DrugBank: Tositumomab I-131 (DB17991)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05435053
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Every 2 weeks (3 mg/kg, maximum of 240 mg) for up to 24 weeks~Nivolumab is an immune checkpoint inhibitor (PD-1-inhibitor).
Trial: NCT05262751
Drug: Nintedanib formulation 1
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nintedanib formulation 1: Monolithic Nintedanib Modified Release Tablet (MR1) as two Prototypes (MR1-1 and MR1-2).
Trial: NCT05262751
Drug: Nintedanib formulation 2
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nintedanib formulation 2: Polyox Nintedanib Modified Release Tablet (MR2) as two Prototypes (MR2-1 and MR2-2).
Trial: NCT05631704
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).
Trial: NCT05693467
Drug: Dexamethasone palmitate emulsion(DXP) plus ropivacaine
RxNorm normalized name: palmitate
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The local infiltration solution in the dexamethasone palmitate emulsion(DXP) plus ropivacaine group will consist of ropivacaine and dexamethasone palmitate emulsion(DXP). For local infiltration, a total of 30mL solution will be prepared for each group, which will include 2mL of DXP(4mg per 1mL) added to 20.5 mL of saline and 7.5mL of 1% ropivacaine added to 15mL of saline for Group A . The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
Trial: NCT06339294
Drug: Clotrimazole Cream
RxNorm normalized name: Clotrimazole Cream
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single time application of clotrimazole ointment was done after aural toilet in external auditory canal via IV catheter
Trial: NCT05078671
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: olaparib treatment
Trial: NCT05078671
Drug: Cobicistat
RxNorm normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmacokinetic booster
Trial: NCT06339294
Drug: Povidone-Iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gelfoam soaked pyodine solution was placed in external auditory canal after aural toilet
Trial: NCT06379542
Drug: XC8
RxNorm normalized name: Xylazine
DrugBank: Xylazine (DB11477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day or 80 mg/day for 7-14 days
Trial: NCT06196580
Drug: repaglinide; midazolam; SHR4640
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: repaglinide; midazolam; SHR4640
Trial: NCT06196580
Drug: repaglinide; midazolam; SHR4640; SHR4640 placebo
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: repaglinide; midazolam; SHR4640; SHR4640 placebo
Trial: NCT06196580
Drug: repaglinide; midazolam; SHR4640 placebo
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: repaglinide; midazolam; SHR4640 placebo
Trial: NCT05299255
Drug: Utidelone
RxNorm normalized name: Utidelone
DrugBank: Utidelone (DB17575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utidelone Versus placebo in Third-line and above treatment of Extensive Small-cell Lung Cancer
Trial: NCT05391360
Drug: Freethiadine tablets(part I)
RxNorm normalized name: iobenguane I-131
DrugBank: Furethidine (DB01464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
Trial: NCT05391360
Drug: entecavir tablets
RxNorm normalized name: Entecavir Tablets
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily for consecutive 28 days
Trial: NCT04827134
Drug: TRIUMEQ
RxNorm normalized name: Triumeq
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TRIUMEQ will be available as fixed dose combination (FDC) dispersible tablets to be administered orally as a dispersion.
Trial: NCT04827134
Drug: DOVATO
RxNorm normalized name: Dovato
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: DOVATO will be available as FDC dispersible tablets to be administered orally as a dispersion.
Trial: NCT05675813
Drug: CHOP+selinexor+5-Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T1 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and selinexor 40mg or 60mg qw (d-7, 1, 8) by traditional 3+3 dose escalation methods and decide RP2D of selinexor.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle.
Trial: NCT05675813
Drug: CHOP+duvelisib+5-Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T2 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and duvelisib 25mg or 50mg bid (d1-14) by traditional 3+3 dose escalation methods and decide RP2D of duvelisib.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle.
Trial: NCT05675813
Drug: CHOP+chidamide+tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T3 genetic subtype, for the remaining 5 cycles, they will receive tislelizumab 200mg d0 ivgtt and chidamide 20mg or 30mg biw (d1,4,8,11) by traditional 3+3 dose escalation methods and decide RP2D of chidamide.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T3 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle.
Trial: NCT02172001
Drug: Iron isomaltoside 1000
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00430833
Drug: candesartan
RxNorm normalized name: Candesartan
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05555147
Drug: nerve block with 0.5% ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After general anesthesia, the patients will receive bilateral infraorbital and infratrochlear nerve block 30 minutes prior to surgery. Infraorbital nerve block is performed while using an extraoral approach. A 25-gauge needle was inserted laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. The index finger of the non-dominant hand was positioned above the infraorbital foramen, and the needle was advanced until it was felt beneath the finger. 2 ml of the 0.5% ropivacaine slowly injected after negative aspiration of blood was confirmed. Inserting the needle 1 cm above the inner canthus, targeting the junction of the orbit and the nasal bone, performed infratrochlear nerve block. After negative aspiration of blood, 1 ml of the 0.5% ropivacaine was injected. Contralateral nerve block was performed in the same manner.
Trial: NCT05918276
Drug: Orelabrutinib and BG
RxNorm normalized name: Orelabrutinib
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Orelabrutinib Orelabrutinib 200mg, po, qd，C2-C7. Twenty-eight days for a cycle.~Drug: BG Bendamustin 70mg/m2, IV, d2\&d3 inC1, and then d1\&d2 inC2-6.Twenty-eight days for a cycle.~Obintuzumab 100mg IV, d1, 900mg d2, 1000mg d8\&d15 in C1, and then 1000mg/m2 IV, d1 in C2-6. Twenty-eight days for a cycle.
Trial: NCT05168462
Drug: Reduced noradrenaline use
RxNorm normalized name: noradrenaline hydrochloride
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced noradrenaline by using a lower MAP target
Trial: NCT06207370
Drug: Tafenoquine
RxNorm normalized name: tafenoquine
DrugBank: Tafenoquine (DB06608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tafenoquine
Trial: NCT06330935
Drug: Tranexamic Acid (TXA)
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 patients will be randomized to A arm and 30 patients to B arm
Trial: NCT04797507
Drug: SHR-1210 plus Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1210: a novel anti-PD-1 antibody Anlotinib: a multi-kinase inhibitor
Trial: NCT04606901
Drug: neostigmine/glycopyrrolate
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: neuromuscular blockade reversal agents
Trial: NCT04606901
Drug: sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: neuromuscular blockade reversal agent
Trial: NCT05634148
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexmedetomidine will be administered 45 minutes before extubation in intervention group
Trial: NCT00002068
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002068
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05010876
Drug: C1 Inhibitor Human
RxNorm normalized name: C1 inhibitor human
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard care + 1000 units of C1 inhibitor during 2 slow infusions of 500 units
Trial: NCT05010876
Drug: Icatibant Injection
RxNorm normalized name: Icatibant Injection
DrugBank: Icatibant (DB06196)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: a single injection of 30 mg subcutaneously
Trial: NCT05372107
Drug: AG-80308
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-80308 Eye Drop Solution
Trial: NCT06046417
Drug: Pramlintide
RxNorm normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pramlintide delivered in a basal-bolus manner.
Trial: NCT06046417
Drug: Lyumjev
RxNorm normalized name: Lyumjev
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lyumjev delivered in a basal-bolus manner.
Trial: NCT06367387
Drug: Patient-Oriented Dosing (POD)
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-oriented dosing (POD) is a promising approach to using buprenorphine or buprenorphine/naloxone to treat individuals with both OUD and chronic pain. It is based on existing evidence related to buprenorphine for the treatment of pain. POD allows participants to receive a daily dosage of bup up to 32mg/day, split up to 4 times per day.~A response-guided dosing strategy, in which buprenorphine or buprenorphine/naloxone doses will be titrated based on a participant response, will be used to identify a dose regimen that is safe and effective. Due to inter-individual pharmacokinetic/pharmacodynamic variability, POD dosing will be individualized based on a participant's pain intensity and interference.
Trial: NCT06367387
Drug: Standard Buprenorphine Dosing Condition
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will continue standard buprenorphine or buprenorphine/naloxone dosing as part of normal clinical care.
Trial: NCT05780034
Drug: AC676
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: AC676 will be given orally (PO) on a 28-day cycle.
Trial: NCT05116826
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg Twice Daily for 7 days
Trial: NCT05029453
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In experimental group, the drug used with apatinib and chemotherapy.
Trial: NCT05761470
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle.~Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle.
Trial: NCT05761470
Drug: Fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzoparib
Trial: NCT05761470
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel
Trial: NCT00002257
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05426018
Drug: SY-009 capsules
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 capsules each time (3 test drugs), 3 times a day (oral administration before breakfast, lunch, dinner or with meals)
Trial: NCT06220552
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200mg D1, Q3W
Trial: NCT05755659
Drug: Fosaprepitant Dimeglumine for Injection
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The specification of Fosaprepitant Dimeglumine for injection is 150 mg, and the usage and dosage is: when preventing nausea and vomiting caused by HEC, this product is used in combination with dexamethasone and 5-HT3 antagonist. The dosage of Fosaprepitant Dimeglumine for injection is 150 mg, and the infusion time is 20-30 minutes. The intravenous infusion is completed 30 minutes before the beginning of chemotherapy on the first day.
Trial: NCT06437951
Drug: Fexuprazan Injection_part 2
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg
Trial: NCT06437951
Drug: Fexuprazan Injection_part 3
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg
Trial: NCT05613777
Drug: BI 425809
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 425809
Trial: NCT04693039
Drug: Phenlarmide
RxNorm normalized name: Octanedioic acid hydroxyamide phenylamide
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
Trial: NCT05395195
Drug: Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin injections (500u/kg) x 9 doses
Trial: NCT05367700
Drug: HS-10382(Part 1: Dose escalation)
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple dose(s) of HS-10382 once daily.
Trial: NCT05367700
Drug: HS-10382(Part 2: Dose expansion)
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS-10382 is administered orally once daily.
Trial: NCT06112353
Drug: Neostigmine Injectable Solution
RxNorm normalized name: neostigmine Injectable Solution
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Examine GI-2 recovery
Trial: NCT06112353
Drug: Sugammadex injection
RxNorm normalized name: sugammadex Injection
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Examine GI-2 recovery
Trial: NCT05337553
Drug: taldefgrobep alfa
RxNorm normalized name: Taldefgrobep alfa
DrugBank: Talditercept alfa (DB16337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DB Phase: 35 mg/50 mg weekly subcutaneous injection
Trial: NCT05337553
Drug: taldefgrobep alfa
RxNorm normalized name: Taldefgrobep alfa
DrugBank: Talditercept alfa (DB16337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extension Phase: 35 mg/50 mg weekly subcutaneous injection
Trial: NCT06044506
Drug: Autologous Natural Killer Cell Therapy
RxNorm normalized name: Hongo Killer
DrugBank: Natural Killer Cell (DB15721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The therapy will be administered intravenously
Trial: NCT04853446
Drug: Dexamethasone 12 mg
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two identically appearing, opaque capsules will be administered: one capsule containing 12 mg of dexamethasone and one capsule containing placebo.
Trial: NCT04853446
Drug: Dexamethasone 24 mg
RxNorm normalized name: dexAMETHasone 24 mg/mL intravenous solution
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two identically appearing, opaque capsules will be administered: two capsules each containing 12mg dexamethasone.